Q-omics provides the consensus-scored RPS29P19 profile across patient tissues and cancer cell-line models. RPS29P19 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPS29P19 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, RPS29P19 RNA expression shows 9,434 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, and UVM as cancer lineages where RPS29P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P19 survival associations across molecular data types. RPS29P19 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P19 RNA expression–survival associations across cancer types. High RPS29P19 expression shows unfavorable associations in BLCA, UVM, KICH and SKCM, but favorable associations in HNSC and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPS29P19 RNA expression.
This table summarizes RPS29P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P19 shows lower tumor expression in KIRC and KIRP and higher tumor expression in BLCA, PAAD and PRAD. The BLCA box plot shows higher RPS29P19 RNA expression in tumor versus normal tissue (log2 FC = +0.407, t-test p = .004).
This table shows molecular features associated with RPS29P19 in patient tissues and cancer cell lines. In patient samples, RPS29P19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
